PMID- 36989310 OWN - NLM STAT- MEDLINE DCOM- 20230331 LR - 20230419 IS - 1932-6203 (Electronic) IS - 1932-6203 (Linking) VI - 18 IP - 3 DP - 2023 TI - Distinctive serum lipidomic profile of IVIG-resistant Kawasaki disease children before and after treatment. PG - e0283710 LID - 10.1371/journal.pone.0283710 [doi] LID - e0283710 AB - Kawasaki Disease (KD) is an acute inflammatory disorder associated with systemic vasculitis. Intravenous immunoglobulin (IVIG) is an effective therapy for KD, yet, about 20% of cases show IVIG resistance with persistent inflammation. The lipid profile in IVIG-resistant KD patients and the relationship between lipid characteristics and IVIG resistance remain unknown. In this study, serum samples from twenty KD patients with different IVIG responses (sensitive, intermediate, or resistant) were collected both before and after treatment, and lipidomic analysis was performed using high-performance liquid chromatography-mass spectrometry. As a result, before treatment, six lipid species were found as the most variant features, in which all the top decreased lipids in the IVIG-resistant group were lysophosphatidylcholine (LPC) and lysophosphatidylethanolamine (LPE), suggesting the potential to be IVIG-resistant markers in pretreatment diagnosis. During treatment, lipidomic changes showed a weaker response in the IVIG-resistant group. After treatment, LPC and LPE species exhibited lower in the IVIG-resistant group and negative correlation with the inflammatory markers, indicating that the unique metabolism may occur among IVIG-responsiveness. These results might contribute to diagnosing IVIG-resistant patients more accurately for alternative therapy and to a better understanding of how lipid metabolism is associated with IVIG sensitiveness/resistance in KD. CI - Copyright: (c) 2023 Chen et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. FAU - Chen, Zhen AU - Chen Z AUID- ORCID: 0000-0001-5339-2499 AD - School of Pharmacy, Jiangsu University, Zhenjiang, Jiangsu, China. AD - Faculty of Health Sciences, Hokkaido University, Sapporo, Hokkaido, Japan. FAU - Sai, Shuji AU - Sai S AD - Department of Pediatrics, Teine-Keijinkai Hospital, Sapporo, Hokkaido, Japan. AD - Institute for Genetic Medicine, Hokkaido University, Sapporo, Hokkaido, Japan. FAU - Nagumo, Kiyoshi AU - Nagumo K AD - Department of Pediatrics, Teine-Keijinkai Hospital, Sapporo, Hokkaido, Japan. FAU - Wu, Yue AU - Wu Y AD - Faculty of Health Sciences, Hokkaido University, Sapporo, Hokkaido, Japan. FAU - Chiba, Hitoshi AU - Chiba H AD - Department of Nutrition, Sapporo University of Health Sciences, Sapporo, Hokkaido, Japan. FAU - Hui, Shu-Ping AU - Hui SP AUID- ORCID: 0000-0001-9973-6461 AD - Faculty of Health Sciences, Hokkaido University, Sapporo, Hokkaido, Japan. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20230329 PL - United States TA - PLoS One JT - PloS one JID - 101285081 RN - 0 (Immunoglobulins, Intravenous) RN - 0 (Lipids) SB - IM MH - Humans MH - Child MH - Infant MH - *Mucocutaneous Lymph Node Syndrome/complications MH - Immunoglobulins, Intravenous/therapeutic use MH - Lipidomics MH - Lipids MH - Retrospective Studies PMC - PMC10057782 COIS- The authors have declared that no competing interests exist. EDAT- 2023/03/30 06:00 MHDA- 2023/03/31 06:42 PMCR- 2023/03/29 CRDT- 2023/03/29 13:44 PHST- 2022/07/12 00:00 [received] PHST- 2023/03/14 00:00 [accepted] PHST- 2023/03/31 06:42 [medline] PHST- 2023/03/29 13:44 [entrez] PHST- 2023/03/30 06:00 [pubmed] PHST- 2023/03/29 00:00 [pmc-release] AID - PONE-D-22-19611 [pii] AID - 10.1371/journal.pone.0283710 [doi] PST - epublish SO - PLoS One. 2023 Mar 29;18(3):e0283710. doi: 10.1371/journal.pone.0283710. eCollection 2023.